Psychotic Disorders - Europe | Statista Market Forecast

Revenue in the Psychotic Disorders market is projected to reach US$1.83bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 0.61%, resulting in a market volume of US$1.89bn by 2029.
In global comparison, most revenue will be generated United States (US$2.26bn in 2024).
In relation to total population figures, per person revenues of US$196.20 are generated in 2024.

Psychotic disorders are severe mental health disorders that cause changes in a person's way of thinking and their perception. Patients often have trouble differentiating between what they perceive and reality. Different types of psychotic disorders include schizophrenia, bipolar disorder, substance-induced psychotic disorder, delusional disorder, and brief psychotic disorder. However, this market only represents the sales of antipsychotic drugs that are used to treat schizophrenia and bipolar disorder.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Otsuka Pharmaceutical, Lundbeck, AbbVie, Allergan plc, Recordati S.p.A., Gadeon Richter, Sumitomo Pharma, Johnson & Johnson / Janssen, Vanda Pharmaceuticals, Alkermes, Eli Lilly, AstraZeneca, and Intra-Cellular Therapies

Antipsychotic drugs: Aripiprazole (Abilify), Asenapine (Saphris), Cariprazine (Vraylar), Clozapine (Clozaril, Versacloz), lumateperone (Caplyta), Lurasidone (Latuda), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Risperidone (Aristada), Ziprasidone (Geodon), Brexpiprazole (Rexulti), Iloperidone (Fanapt), and Paliperidone (Invega)

Psychotherapy
Talk therapy
Herbal medicines
Digital health apps
Deep Brain Stimulation (DBS)

The Psychotic Disorders market in Europe is experiencing significant growth and development due to several factors. Customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors all contribute to the growth and development of this market.Customer preferences play a crucial role in driving the growth of the Psychotic Disorders market in Europe. There is an increasing demand for effective treatments and therapies for psychotic disorders, as more people are being diagnosed with these conditions. Customers are seeking innovative and personalized solutions that can help them manage their symptoms and improve their quality of life. This has led to the development of new drugs and therapies that target specific symptoms and provide better outcomes for patients.Trends in the market also contribute to the growth of the Psychotic Disorders market in Europe. One major trend is the increasing use of digital technologies in the diagnosis and treatment of psychotic disorders. Telemedicine and remote monitoring have become more prevalent, allowing patients to receive care from the comfort of their own homes. This trend has been accelerated by the COVID-19 pandemic, which has highlighted the importance of remote healthcare solutions. Additionally, there is a growing focus on early intervention and prevention of psychotic disorders, leading to the development of new screening tools and interventions.Local special circumstances in different European countries also impact the growth of the Psychotic Disorders market. Each country has its own healthcare system and policies, which can influence the availability and accessibility of treatments for psychotic disorders. Some countries may have a higher prevalence of psychotic disorders, leading to a greater demand for treatments. Others may have limited resources and infrastructure, making it challenging to provide adequate care for patients. These local special circumstances shape the market dynamics and drive the development of innovative solutions tailored to the specific needs of each country.Underlying macroeconomic factors also play a role in the growth of the Psychotic Disorders market in Europe. Economic growth and increased healthcare spending contribute to the availability of resources for research and development of new treatments. Government policies and regulations also influence the market, with some countries providing incentives for the development of innovative therapies. Additionally, the aging population in Europe is a significant factor driving the growth of the Psychotic Disorders market, as older individuals are more likely to develop psychotic disorders.In conclusion, the Psychotic Disorders market in Europe is experiencing growth and development driven by customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors. The demand for effective treatments, the use of digital technologies, and the focus on early intervention are all contributing to the expansion of this market. Additionally, the unique healthcare systems and policies in different European countries, as well as the aging population, shape the market dynamics and drive the development of innovative solutions.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.